27. Transmissible Spongiform Encephalopathies and Plasma Products

  1. Joseph Bertolini3,
  2. Neil Goss4 and
  3. John Curling5
  1. Luisa Gregori1,
  2. David Asher1 and
  3. Dorothy Scott2

Published Online: 14 DEC 2012

DOI: 10.1002/9781118356807.ch27

Production of Plasma Proteins for Therapeutic Use

Production of Plasma Proteins for Therapeutic Use

How to Cite

Gregori, L., Asher, D. and Scott, D. (2013) Transmissible Spongiform Encephalopathies and Plasma Products, in Production of Plasma Proteins for Therapeutic Use (eds J. Bertolini, N. Goss and J. Curling), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9781118356807.ch27

Editor Information

  1. 3

    CSL Biotherapies, Broadmeadows, Victoria, Australia

  2. 4

    Further Options Pty. Ltd., Eaglemont, Victoria, Australia

  3. 5

    John Curling Consulting AB, Uppsala, Sweden

Author Information

  1. 1

    Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, MD, USA

  2. 2

    Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD, USA

Publication History

  1. Published Online: 14 DEC 2012
  2. Published Print: 21 DEC 2013

ISBN Information

Print ISBN: 9780470924310

Online ISBN: 9781118356807

SEARCH

Keywords:

  • TSE, and plasma products;
  • sCJD, common human TSE;
  • vCJD epidemiology;
  • sCJD/vCJD differences;
  • plasma transfusion risk

Summary

This chapter contains sections titled:

  • Human Transmissible Spongiform Encephalopathy Diseases and Prion Protein

  • Epidemiology of Variant Creutzfeldt-Jakob Disease

  • TSE Infectivity in Blood

  • Risk of Transfusion Transmission from VCJD-Infected Blood Components

  • Reduction of VCJD Risks in Blood Components and Plasma Products

  • TSE Screening Tests

  • Recent Developments of Interest and Future Issues

  • Disclaimer

  • References